226 related articles for article (PubMed ID: 21684737)
1. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
Lee J; Kim KH; Jeong S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
[TBL] [Abstract][Full Text] [Related]
2. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
5. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.
Chen S; Chen L; Le NT; Zhao C; Sidduri A; Lou JP; Michoud C; Portland L; Jackson N; Liu JJ; Konzelmann F; Chi F; Tovar C; Xiang Q; Chen Y; Wen Y; Vassilev LT
Bioorg Med Chem Lett; 2007 Apr; 17(8):2134-8. PubMed ID: 17303421
[TBL] [Abstract][Full Text] [Related]
8. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.
Marchetti F; Cano C; Curtin NJ; Golding BT; Griffin RJ; Haggerty K; Newell DR; Parsons RJ; Payne SL; Wang LZ; Hardcastle IR
Org Biomol Chem; 2010 May; 8(10):2397-407. PubMed ID: 20448898
[TBL] [Abstract][Full Text] [Related]
11. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Schultz C; Link A; Leost M; Zaharevitz DW; Gussio R; Sausville EA; Meijer L; Kunick C
J Med Chem; 1999 Jul; 42(15):2909-19. PubMed ID: 10425100
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
[TBL] [Abstract][Full Text] [Related]
14. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
15. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
Wee XK; Yeo WK; Zhang B; Tan VB; Lim KM; Tay TE; Go ML
Bioorg Med Chem; 2009 Nov; 17(21):7562-71. PubMed ID: 19783149
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
[TBL] [Abstract][Full Text] [Related]
20. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
